Disease Flare after Treatment Discontinuation in a Patient with EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib

Journal of Thoracic Oncology

Volumn 7, Issue 8, 2012, Pages

  Pop, Oana ^a   Pirvu, Augustin ^b   Toffart, Anne Claire ^a   Moro Sibilot, Denis ^a  

^a Department of Oncology ^*  (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BEVACIZUMAB; CISPLATIN; CRIZOTINIB; DOCETAXEL; MICROTUBULE PROTEIN; PEMETREXED; PROTEIN EML4; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN METASTASIS; CANCER GROWTH; CANCER RELAPSE; CANCER SIZE; CASE REPORT; CERVICAL LYMPH NODE; DISEASE EXACERBATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; MEDIASTINUM LYMPH NODE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84863827626     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318257fc1d     Document Type: Article

References (5)

1. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008;3:13-17.
2. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008;14:4275-4283.
3. Chaft JE, Oxnard GR, Sima CS, Kris MG, Miller VA, Riely GJ. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res 2011;17:6298-6303.
4. Soda M, Takada S, Takeuchi K, et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci USA 2008;105:19893-19897.
5. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011;12:1004-1012.